Johnson & Johnson: Steady Growth and Margin Expansion, But Wait for a Discount

🧬💊💉Business Overview

Founded in 1886, Johnson & Johnson (J&J) is a diversified global healthcare leader operating across pharmaceuticals, medical technologies, and—until recently—consumer health. With over 60 consecutive years of dividend increases, the company exemplifies financial resilience, strong free cash flows, and disciplined capital allocation.

Following the spinoff of Kenvue (its consumer health unit), J&J has sharpened its focus on high-margin, innovation-led therapeutic areas such as oncology, immunology, and neuroscience. Backed by a robust pipeline, substantial R&D investment, and exposure to essential healthcare demand, J&J is well-positioned for inflation-beating, defensive growth over the long term.

💵Revenue Exposure & Diversification

The revenues are geographically diversified over the following geographic segments:

• United States: 56.63%
  • 1-Year Revenue Growth = 8.31% (5Y CAGR: 3.63%)
• Europe: 22.76%
  • 1-Year Revenue Growth = -0.97% (5Y CAGR: 1.82%)
• Asia-Pacific, Africa: 15.30%
  • 1-Year Revenue Growth = -1.18% (5Y CAGR: -2.66%)
• Western Hemisphere excluding U.S. : 5.31%
  • 1-Year Revenue Growth = 3.63% (5Y CAGR: -4.52%)

It's also diversified across several business segments:

• Oncology (Innovative Medicine): 23.40%
  • 1-Year Revenue Growth = 17.67% (5Y CAGR: 14.21%)
  • Estimated Operating Margin: ~29-34%
• Immunology (Innovative Medicine): 20.07%
  • 1-Year Revenue Growth = -1.24% (5Y CAGR: 5.03%)
  • Estimated Operating Margin: ~29-34%
• Surgery (Medical Technology): 11.08%
  • 1-Year Revenue Growth = -1.91% (5Y CAGR: 0.71%)
  • Estimated Operating Margin: ~9-14%
• Orthopaedics (Medical Technology): 10.31%
  • 1-Year Revenue Growth = 2.42% (5Y CAGR: 0.71%)
  • Estimated Operating Margin: ~9-14%
• Cardiovascular (Medical Technology): 8.68%
  • 1-Year Revenue Growth = 21.37% (5Y CAGR: 20.79%)
  • Estimated Operating Margin: ~9-14%
• Neuroscience (Innovative Medicine): 8.01%
  • 1-Year Revenue Growth = -0.35% (5Y CAGR: 2.37%)
  • Estimated Operating Margin: ~29-34%
• Vision (Medical Technology): 5.79%
  • 1-Year Revenue Growth = 1.46% (5Y CAGR: 2.16%)
  • Estimated Operating Margin: ~9-14%
• Pulmonary Hypertension (Innovative Medicine): 4.82%
  • 1-Year Revenue Growth = 12.24% (5Y CAGR: 10.30%)
  • Estimated Operating Margin: ~29-34%
• Cardiovascular / Metabolism / Other (Innovative Medicine): 4.01%
  • 1-Year Revenue Growth = -2.97% (5Y CAGR: -7.26%)
  • Estimated Operating Margin: ~29-34%
• Infectious Diseases (Innovative Medicine): 3.82%
  • 1-Year Revenue Growth = -23.13% (5Y CAGR: -0.10%)
  • Estimated Operating Margin: ~29-34%

🎯Key Insights & Assumptions

• Revenue Growth: 5-Year (CAGR): 1.60% | Last Year: 4.30%
  • Expected to progress gradually to around ~4.35%, the risk-free rate of its currency (10-YR U.S. bond yield) given the company maturity and stability.
• Free Cash Flow Growth: 5-Year (CAGR): -0.08% | Last Year: 8.74%
  • Also in line with the revenues, it is expected the free cash flow growth to be stabilized around the risk-free rate of ~4.35%.
• Operating Margin: 5-Year Avg: 25.37% | Last Year: 23.69%
  • Expected to expand to ~28% as the portfolio shifts toward higher-margin segments.
• Return on Invested Capital (ROIC): 5-Year Avg: 17.36% | Last Year: 21.21%
  • Expected to remain strong around ~17-23%, given its historical averages and current values, gradually converging to ~15% in the long run, a little above the U.S. industry average of ~13%.
• Dividend Growth: 5-Year (CAGR): 5.54% | Last Year: 4.47%
  • Projected to grow near ~4.35% in line with earnings and FCF.
• Dividend Payout Ratio: 5-Year Avg: 72.34% | Last Year: 84.80%
  • Expected to stabilize around 75-80% given the slow growth but the conscious and reliability of the business.

📈Business Valuation

To assess Johnson & Johnson intrinsic value, we'll be using these valuation methods:

• Discounted Cash Flow (DCF) - Intrinsic value is estimated by projecting Johnson & Johnson free cash flows over the next 10 years and discounting them to present value.
• Dividend Discount Model (DDM) - Intrinsic value is estimated by projecting Johnson & Johnson dividends over the next 10 years and discounting them to present value.
• Historical Dividend Yield - estimation of fair value using a relation to the historical dividend yield that the company has traded over the last 10 years.

Given that the Historical method assumes a mean reversion, that may not occur, DCF and DDM models will be more heavily weighted.

Discounted Cash Flow (Weight: 50%)

📌 Key Assumptions

• Revenue Growth (CAGR) is estimated to be around 4.67% in Year 1, 4.85% in Years 2-5 , tapering to 4.35% (risk-free rate of the U.S. dollar - 10-YR bond yield) in perpetuity.
• Operating Margin increasing gradually to 28% , driven by the company growth and investment on its higher margin segments.
• Cost Of Capital begins at 8.90% (considering its global revenue exposure, risk-free rate of its currency, and Moody's credit rating of Aaa) and then gradually decreasing to 8.05% (the U.S. industry average).
• ROIC terminal value will be set to ~15% (a little above the U.S. industry average of ~13%).

💰 Fair Value Estimate

Based on the DCF model, Johnson & Johnson estimated fair value is $146.57, suggesting that currently the stock may be overvalued.

Dividend Discount Model (Weight: 30%)

📌 Key Assumptions

• Dividend Growth begins at 5.54% (5-year CAGR) and then tapering to a stable rate equal to the risk free rate (10-YR U.S. Dollars bond yield) of 4.35%.
• Discount Rate or required return will be equal to 8.90%, the cost of capital (WACC) calculated during the DCF valuation.

💰 Fair Value Estimate

Based on the DDM model, Johnson & Johnson estimated fair value is $126.24, suggesting that currently the stock may be overvalued.

Historical Dividend Yield (Weight: 20%)

• Current Dividend Yield: ~3.10%
• 10-Year Median Dividend Yield: ~2.74%

💰 Fair Value Estimate

This suggests that the stock is trading below its intrinsic valuation, indicating a potential upside of 11.61% if it reverts back to its historical median.

Using this method, its fair value should be $187.43.

Summary

Blending all three valuation methods by their assigned weights, it is estimated that the fair value of Johnson & Johnson is $148.64.

At current prices, Johnson & Johnson appears overvalued relative to its fundamentals. While not cheap, it remains a high-quality, resilient compounder with a strong dividend track record and durable earnings power. A better entry point may offer a more compelling margin of safety, but for long-term income-oriented investors, J&J remains a defensive hold with inflation-hedging potential.